TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is a Healthcare company (Medical - Devices) with a market capitalization of $142M. The Maz Rating grades it against the other companies in its sector.
TriSalus Life Sciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.29, TriSalus Life Sciences, Inc. trades at 3.0x sales and 194.8x book value. Over the last twelve months it generated about $47M of revenue and a net loss of $31M. It runs a gross margin of 86.5%, an operating margin of -63.0% and a net margin of -56.6%. It shows return on equity of 759.7%, return on invested capital of -65.2% and a free cash flow yield of -22.1%. On the balance sheet: a debt-to-equity ratio of 49.55 and a current ratio of 4.22. Over the past 52 weeks the share price ranged from $2.17 to $7.95, with a beta of 0.51.
TriSalus Life Sciences, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.